Table 3 Weighted mean differences in pulse wave velocity between the ARB treatment and control groups according to the type of drugs in treatment group
From: The impact of angiotensin receptor blockers on arterial stiffness: a meta-analysis
Subgroups | Studies (n) | WMD; 95% CI; P | I2 (P) |
|---|---|---|---|
baPWV | |||
Telmisartan | 9 | −100.82; −145.66 to −55.98; 0.000 | 96.3% (0.000) |
Losartan | 4 | −81.30; −204.54 to −41.95; 0.196 | 96.4% (0.000) |
Valsartan | 19 | −104.59; −154.01 to −55.18; 0.000 | 95.7% (0.000) |
Candesartan | 4 | −139.49; −288.74 to 9.76; 0.067 | 71.0% (0.016) |
Irbesartan | 3 | −69.70; −176.80 to 37.40; 0.202 | 0.0% (0.723) |
cfPWV | |||
Losartan | 4 | 37.02; −122.88 to 48.86; 0.398 | 92.7% (0.000) |
Valsartan | 6 | −65.58; −124.84 to −6.32; 0.030 | 69.0% (0.006) |
Candesartan | 3 | −3.77; −47.53 to 39.99; 0.866 | 0.0% (0.559) |
